



IPW

PATENT
ATTORNEY DOCKET NO. 06727/012001

Certificate of Mailing: Date of Deposit: March 28, 2005

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Christine M. Colbert

Printed name of person mailing correspondence

Christine M. Colbert
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Robert Mulroy et al.	Art Unit:	1632
Serial No.:	10/624,380	Examiner:	Not Yet Assigned
Filed:	July 22, 2003	Customer No.:	21559
Title:	NON-GLYCOSYLATED HUMAN ALPHA-FETOPROTEIN, METHODS OF PRODUCTION, AND USES THEREOF		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents. Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office action on the merits.

If there are any charges or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully submitted,



TODD ARMSTRONG, P.H.D.
REG. NO. 54,590

Date: 28 March 2005

for

Paul T. Clark
Reg. No. 30,162

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	06727/012001
	Serial No.	10/624,380
	Applicant	Robert Mulroy et al.
	Filing Date	July 22, 2003
	Group	1632
	IDS Filed	March 28, 2005
	Customer Number	21559

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	5,965,528	10/12/99	Robert A. Murgita	514	12	01/24/95
	6,013,857	01/11/00	Herman A. Deboer et al.	800	15	06/05/95
	6,288,034	09/11/01	Robert A. Murgita	514	12	11/05/98
	6,331,611	12/18/01	Robert A. Murgita	530	350	07/21/95
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	EP 0 001 812	05/16/79	Europe			
	EP 0 487 229	09/24/97	Europe			
	JP 2005866	01/10/90	Japan (Abstract)			
	WO 86/04241	07/31/86	PCT			
	WO 93/05774	04/01/93	PCT			
	WO 94/10199	05/11/94	PCT			
	WO 95/00637	01/05/95	PCT			
	WO 96/09377	03/28/96	PCT			
	WO 96/22787	08/01/96	PCT			
	WO 01/15709	03/08/01	PCT			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Abramsky et al., "A Role of Alpha-Fetoprotein in Autoimmune Diseases," <i>Annals New York Academy of Sciences</i> 417:108-116 (1983).					
	Abramsky et al., "Alpha-Fetoprotein Suppresses Experimental Allergic Encephalomyelitis," <i>Journal of Neuroimmunology</i> 2:1-7 (1982).					
EXAMINER			DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	06727/012001
		Serial No.	10/624,380
		Applicant	Robert Mulroy et al.
		Filing Date	July 22, 2003
		Group	1632
		IDS Filed	March 28, 2005
		Customer Number	21559
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Aoyagi et al., "Differential Reactivity of Alpha-Fetoprotein with Lectins and Evaluation of its Usefulness in the Diagnosis of Hepatocellular Carcinoma," <i>Gann</i> 75:809-815 (1984).
	Bennett et al., "Similarity Between Natural and Recombinant Human Alpha-Fetoprotein as Inhibitors of Estrogen-Dependent Breast Cancer Growth," <i>Breast Cancer Research and Treatment</i> 45:169-179 (1997).
	Biddle et al., "Specific Cytoplasmic Alpha-Fetoprotein Binding Protein in MCF-7 Human Breast Cancer Cells and Primary Breast Cancer Tissue," <i>Breast Cancer Research and Treatment</i> 10:279-286 (1987).
	Birrer et al., "The Immunology of Alphafetoprotein," <i>Journal of Tumor Marker Oncology</i> 14:55-62 (1999).
	Boismenu et al., "Expression of Domains of Mouse Alpha-Fetoprotein in <i>Escherichia Coli</i> ," <i>Life Sciences</i> 43:673-681 (1988).
	Brenner et al., "Immunosuppression of Experimental Autoimmune Myasthenia Gravis by Alpha-Fetoprotein Rich Formation," <i>Immunology Letters</i> 3:163-167 (1981).
	Brenner et al., "Influence of Alpha-Fetoprotein on the <i>in Vitro</i> and <i>in Vivo</i> Immune Response to Acetylcholine Receptor," <i>Annals New York Academy of Sciences</i> 377:208-221 (1981).
	Brenner et al., "Inhibitory Effect of Alpha-Fetoprotein on the Binding of Myasthenia Gravis Antibody to Acetylcholine Receptor," <i>Proc. Natl. Acad. Sci. USA</i> 77:3635-3639 (1980).
	Buamah et al., "Serum Alpha-Fetoprotein Heterogeneity as a Means of Differentiating Between Primary Hepatocellular Carcinoma and Hepatic Secondaries," <i>Clinica. Chimica. Acta.</i> 139:313-316 (1984).
	Buschman et al., "Experimental Myasthenia Gravis Induced in Mice by Passive Transfer of Human Myasthenic Immunoglobulin," <i>Journal of Neuroimmunology</i> 13:315-330 (1987).
	Caturla et al., "The Thyroid Hormone Down-Regulates the Mouse Alpha-Fetoprotein Promoter," <i>Molec. and Cell. Endocrin.</i> 135:139-145 (1997).
	Cohen et al., "Suppression by Alpha-Fetoprotein of Murine Natural Killer Cell Activity Stimulated <i>in Vitro</i> and <i>in Vivo</i> by Interferon and Interleukin 2," <i>Scand. J. Immunol.</i> 23:211-223 (1986).
	Dattwyler et al., "Binding of Alpha-Fetoprotein to Murine T Cells," <i>Nature</i> 256:656-657 (1975).
	Dudich et al., "Growth-Regulative Activity of Human Alpha-Fetoprotein for Different Types of Tumor and Normal Cells," <i>Tumor Biology</i> 19:30-40 (1998).
	Galarneau et al., "The Alpha ₁ -Fetoprotein Locus is Activated by a Nuclear Receptor of the <i>Drosophila</i> FTZ-F1 Family," <i>Molec. and Cell. Biol.</i> 16:3853-3865 (1996).
EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	06727/012001
	Serial No.	10/624,380
	Applicant	Robert Mulroy et al.
	Filing Date	July 22, 2003
	Group	1632
	IDS Filed	March 28, 2005
	Customer Number	21559

	Gershwin et al., "The Influence of Alpha-Fetoprotein on Moloney Sarcoma Virus Oncogenesis: Evidence for Generation of Antigen Nonspecific Suppressor T Cells," <i>The Journal of Immunology</i> 121:2292-2297 (1978).
	Gibbs et al., "Structure, Polymorphism, and Novel Repeated DNA Elements Revealed by a Complete Sequence of the Human Alpha-Fetoprotein Gene," <i>Biochemistry</i> 26:1332-1343 (1987).
	Giuliani et al., "Synthesis and Characterization of a Recombinant Fragment of Human Alpha-Fetoprotein with Antigenic Selectivity Versus Albumin," <i>Protein Engineering</i> 2:605-610 (1989).
	Glazier et al., "Graft-Versus-Host Disease in Cyclosporin A-Treated Rats After Syngeneic and Autologous Bone Marrow Reconstitution," <i>J. Exp. Med.</i> 158:1-8 (1983).
	Goidl et al., "Studies on the Mechanisms of Alpha-Fetoprotein Induction of Immune Suppressive Activity," <i>from Developmental Immunobiology, Proceedings of the Fifth Irwin Strasburger Memorial Seminar on Immunology</i> eds. Siskind et al., 35-55 (1979).
	Hamel et al., "Phenotype and Function of Bone Marrow-Derived T- and Non-T-Cells Activated <i>in Vitro</i> by Alpha-Fetoprotein," <i>Biological Activities of Alpha₁-Fetoprotein</i> eds. Mizejewski et al. 1:167-177 (1987).
	Heyward et al., "Early Detection of Primary Hepatocellular Carcinoma by Screening for Alpha-Fetoprotein in High-Risk Families," <i>The Lancet</i> 2:1161-1162 (1983).
	Hooper et al., "Human AFP Inhibits Cell Proliferation and NK-Like Cytotoxic Activity Generated in Autologous, but not in Allogeneic Mixed Lymphocyte Reactions," <i>Biological Activities of Alpha₁-Fetoprotein</i> eds. Mizejewski et al. 2:183-197 (1989).
	Hooper et al., "Regulation of Murine T-Cell Responses to Autologous Antigens by Alpha-Fetoprotein," <i>Cellular Immunology</i> 63:417-425 (1981).
	Hooper et al., "Selective Inhibition of Murine T-Cell Proliferation and Lymphokine-Activated Natural Killer Cell Function by Alpha-Fetoprotein," <i>Biological Activities of Alpha₁-Fetoprotein</i> eds. Mizejewski et al. 1:153-165 (1987).
	Hooper et al., "Suppression of Primary and Secondary Autologous Mixed Lymphocyte Reactions by Murine Alphafetoprotein," <i>Oncodevelopmental Biology and Medicine</i> 3:151-160 (1982).
	Hoskin et al., "Analysis of Pregnancy-Associated Immunoregulatory Pathways," <i>Alpha-Fetoprotein and Congenital Disorders</i> 59-78 (1985).
	Hoskin et al., "In Vitro Activation of Bone Marrow-Derived T-and Non-T-Cell Subsets by Alpha-Fetoprotein," <i>Cellular Immunology</i> 96:163-174 (1985).
	Hoskin et al., "Specific Maternal Anti-Fetal Lymphoproliferative Responses and Their Regulation by Natural Immunosuppressive Factors," <i>Clin. Exp. Immunol.</i> 76:262-267 (1989).
EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	06727/012001
		Serial No.	10/624,380
		Applicant	Robert Mulroy et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 22, 2003
		Group	1632
(37 C.F.R. § 1.98(b))		IDS Filed	March 28, 2005
		Customer Number	21559

	Innis et al., "Amplification of Alpha-Fetoprotein Complementary DNA by Insertion into a Bacterial Plasmid," <i>Archives of Biochemistry and Biophysics</i> 195:128-135 (1979).
	Ishiguro et al., "Serum Alpha-Fetoprotein Subfractions in Patients with Primary Hepatoma or Hepatic Metastasis of Gastric Cancer," <i>Cancer</i> 55:156-159 (1985).
	Jacobson et al., "Inhibition of Estrogen-Dependent Breast Cancer Growth by a Reaction Product of Alpha-Fetoprotein and Estradiol," <i>Cancer Research</i> 50:415-420 (1990).
	Jiang et al., "Role of CD8+ T Cells in Murine Experimental Allergic Encephalomyelitis," <i>Science</i> 256:1213-1215 (1992).
	Keller et al., "Immunosuppressive Properties of AFP: Role of Estrogens," from <i>Onco-Developmental Gene Expression</i> eds. Fishman et al. 287-295 (1976).
	Kerr et al., "The Bladder as a Bioreactor: Urothelium Production and Secretion of Growth Hormone into Urine," <i>Nat. Biotechnol.</i> 16:75-79 (1998).
	Kikutani et al., "The Murine Autoimmune Diabetes Model: NOD and Related Strains," <i>Advances in Immunology</i> 51:285-322 (1992).
	Koyama et al., "Lectin Affinity Electrophoretic Demonstration of Tissue Specificity and Malignant Alteration of Human α -Fetoprotein Isoforms Produced in Transgenic Mice," <i>Biochemical and Biophysical Research Communications</i> 223:757-761 (1996).
	Line et al., "Medical Potential of AFP as a Tumor Imaging Agent," <i>Biological Activities of Alpha-Fetoprotein</i> eds. Mizejewski et al. 2:139-148 (1989).
	Lu et al., "Alpha-Fetoprotein Inhibits Macrophage Expression of Ia Antigens," <i>The Journal of Immunology</i> 132:1722-1727 (1984).
	Masuda et al., "Selective Antitumor Effect of Thioether-Linked Immunotoxins Composed of Gelonin and Monoclonal Antibody to Alpha-Fetoprotein or its F(ab') ₂ Fragment," <i>Tumor Biol.</i> 15:175-183 (1994).
	Mizejewski, "Alpha-Fetoprotein Testing: Regulatory and Technical Considerations," <i>Laboratory Management</i> (1987).
	Morinaga et al., "Primary Structures of Human Alpha-Fetoprotein and its mRNA," <i>Proc. Natl. Acad. Sci. USA</i> 80:4604-4608 (1983).
	Moro et al., "Monoclonal Antibodies Directed Against a Widespread Oncofetal Antigen: The Alpha-Fetoprotein Receptor," <i>Tumor Biol.</i> 14:116-130 (1993).
EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	06727/012001
		Serial No.	10/624,380
		Applicant	Robert Mulroy et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	July 22, 2003
		Group	1632
(37 C.F.R. § 1.98(b))		IDS Filed	March 28, 2005
		Customer Number	21559

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Murgita et al., "Adult Murine T Cells Activated <i>in Vitro</i> by Alpha-Fetoprotein and Naturally Occurring T Cells in Newborn Mice: Identity in Function and Cell Surface Differentiation Antigens," <i>Proc. Natl. Acad. Sci. USA</i> 75:2897-2901 (1978).
	Murgita et al., "Alpha-Fetoprotein Induces Suppressor T Cells <i>in Vitro</i> ," <i>Nature</i> 267:257-259 (1977).
	Murgita et al., "Characterization of Murine Newborn Inhibitory T Lymphocytes: Functional and Phenotypic Comparison with an Adult T Cell Subset Activated <i>in Vitro</i> by Alpha-Fetoprotein," <i>Eur. J. Immunol.</i> 11:957-964 (1981).
	Murgita et al., "Effects of Human Alpha-Fetoprotein on Human B and T Lymphocyte Proliferation <i>in Vitro</i> ," <i>Clin. Exp. Immunol.</i> 33:347-356 (1978).
	Murgita et al., "The Effects of Mouse Alpha-Fetoprotein on T-Cell-Dependent and T-Cell-Independent Immune Responses <i>in Vitro</i> ," <i>Scand. J. Immunol.</i> 5:1215-1220 (1976).
	Murgita, "The Immunosuppressive Role of Alpha-Fetoprotein During Pregnancy," <i>Scand. J. Immunol.</i> 5:1003-1014 (1976).
	Murgita et al., "Regulation of Immune Functions in the Fetus and Newborn," <i>Prog. Allergy</i> 29:54-133 (1981).
	Murgita et al., "Selective Immunoregulatory Properties of Alpha-Fetoprotein," <i>La Ricerca Clin. Lab.</i> 9:327-342 (1979).
	Murgita et al., "Suppression of the Immune Response by Alpha-Fetoprotein I. The Effect of Mouse Alpha-Fetoprotein on the Primary and Secondary Antibody Response," <i>The Journal of Experimental Medicine</i> 141:269-286 (1975).
	Murgita et al., "Suppression of the Immune Response by Alpha-Fetoprotein II. The Effect of Mouse Alpha-Fetoprotein on Mixed Lymphocyte Reactivity and Mitogen-Induced Lymphocyte Transformation," <i>The Journal of Experimental Medicine</i> 141:440-452 (1975).
	Nelson et al., "Maternal-Fetal Disparity in HLA Class II Alloantigens and the Pregnancy-Induced Amelioration of Rheumatoid Arthritis," <i>The New England Journal of Medicine</i> 329:466-471 (1993).
	Nishi et al., "Expression of Rat Alpha-Fetoprotein cDNA in <i>Escherichia coli</i> and in Yeast," <i>J. Biochem.</i> 104:968-972 (1988).
	O'Neill et al., "Regulation of Human Lymphocyte Activation by Alpha-Fetoprotein: Evidence for Selective Suppression of Ia-Associated T-Cell Proliferation <i>in Vitro</i> ," <i>Oncodevelopmental Biology and Medicine</i> 3:135-150 (1982).
	Peck et al., "Cellular and Genetic Restrictions in the Immunoregulatory Activity of Alpha-Fetoprotein I. Selective Inhibition of Anti-Ia-Associated Proliferative Reactions," <i>J. Exp. Med.</i> 147:667-683 (1978).
EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	06727/012001
		Serial No.	10/624,380
		Applicant	Robert Mulroy et al.
		Filing Date	July 22, 2003
		Group	1632
		IDS Filed	March 28, 2005
Customer Number	21559		

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Peck et al., "Cellular and Genetic Restrictions in the Immunoregulatory Activity of Alpha-Fetoprotein II. Alpha-Fetoprotein-Induced Suppression of Cytotoxic T Lymphocyte Development," <i>J. Exp. Med.</i> 148:360-372 (1978).
	Peck et al., "Cellular and Genetic Restrictions in the Immunoregulatory Activity of Alpha-Fetoprotein III. Role of the MLC-Stimulating Cell Population in Alpha-Fetoprotein-Induced Suppression of T Cell-Mediated Cytotoxicity," <i>J. of Immunology</i> 128:1134-1140 (1982).
	Sambrook et al., "Expression of Cloned Genes in <i>Escherichia coli</i> ," <i>Molecular Cloning</i> 17:1-44 (1989).
	Sell, "Alphafetoprotein," <i>Cancer Markers Diagnostic and Developmental Significance</i> 249-293 (1980).
	Semeniuk et al., "Immunoregulation by Recombinant Alpha-Fetoproteins Produced in Eukaryotic and Prokaryotic Expression Systems," Abstract 2799, <i>Experimental Biology 94TM</i> (1994).
	Soto et al., "Control of Growth of Estrogen-Sensitive Cells: Role for Alpha-Fetoprotein," <i>Proc. Natl. Acad. Sci. USA</i> 77:2084-2087 (1980).
	Van Oers, et al., "Isolation and Characterization of a Distinct Immunoregulatory Isoform of Alpha-Fetoprotein Produced by the Normal Fetus," <i>J. Exp. Med.</i> 170:811-825 (1989).
	Van Oers et al., "Analytical- and Preparative-Scale Separation of Molecular Variants of Alpha-Fetoprotein by Anion-Exchange Chromatography on Monobead TM Resins," <i>Journal of Chromatography</i> 525:59-69 (1990).
	Villacampa et al., "Alpha-Fetoprotein Receptors in a Human Breast Cancer Cell Line," <i>Biochemical and Biophysical Research Communications</i> 122:1322-1327 (1984).
	Yamamoto et al., "Expression of Human Alpha-Fetoprotein in Yeast," <i>Life Sciences</i> 46:1679-1686 (1990).
EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	